Ribozyme Pharmaceuticals, Inc. (RPI), the Boulder CO pharmaceutical and
biotech company, will disclose important corporate and product news concerning
its unique cancer drug, Angiozyme(TM):
11:00 AM, Wednesday - November 17 in Denver.
A 30-minute press conference will be held at the Adam's Mark Hotel to
review the Company's most recent success. Lunch will be served.
WHAT: Boulder, CO's RPI is the world-leader for the development
of ribozyme-based therapeutics. RPI presently has several
drug compounds in development, of these Angiozyme -- it's
cancer drug -- has made significant progress. Angiozyme
is now in human clinical trials at the Cleveland Clinic
Foundation and has taken an important step forward ...
making both clinical history and industry news. RPI
CEO & President, Ralph E. Christoffersen, Ph.D., and other
senior RPI staff, will explain Angiozyme and its recent
history-making leap, an achievement which may be of great
significance to cancer patients everywhere.
WHERE/WHEN: An informal press conference will be held at 11:00 AM at
the Adam's Mark Hotel, Directors Row # I, Plaza Building,
Ground Floor.
Lunch will be served at 11:30
Interviews with Dr. Christoffersen and members of the
Cleveland Clinic medical staff may be scheduled to follow
the press conference.
Beta-VHS video tape and printed materials will be provided
for media use.
RSVP: Elaine Taylor / RPI 303-546-8110
Freeeman / Mc Cue 714-557-3663
RPI / NASDAQ: RZYM
WWW.RPI.COM
CONTACT: Elaine Taylor of Ribozyme Pharmaceuticals Inc., 303-546-8110; or
Daniel McCue, 714-231-6036, or Tracy Bossenbroek, 714-557-3663, both of
Freeman/McCue Public Relations, for Ribozyme Pharmaceuticals Inc.
|
